Healthcare of Ontario Pension Plan Trust Fund Sells 209,698 Shares of Eli Lilly and Company (NYSE:LLY)

Healthcare of Ontario Pension Plan Trust Fund reduced its position in Eli Lilly and Company (NYSE:LLY) by 69.8% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 90,627 shares of the company’s stock after selling 209,698 shares during the period. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Eli Lilly and Company were worth $80,290,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Blueshift Asset Management LLC bought a new stake in Eli Lilly and Company in the 3rd quarter valued at about $881,000. WorthPointe LLC raised its stake in Eli Lilly and Company by 77.0% in the 3rd quarter. WorthPointe LLC now owns 469 shares of the company’s stock valued at $416,000 after acquiring an additional 204 shares during the period. Freedom Investment Management Inc. raised its stake in Eli Lilly and Company by 8.2% in the 3rd quarter. Freedom Investment Management Inc. now owns 4,142 shares of the company’s stock valued at $3,670,000 after acquiring an additional 314 shares during the period. Cynosure Group LLC raised its stake in Eli Lilly and Company by 21.7% in the 3rd quarter. Cynosure Group LLC now owns 2,122 shares of the company’s stock valued at $1,880,000 after acquiring an additional 379 shares during the period. Finally, RS Crum Inc. increased its position in shares of Eli Lilly and Company by 29.6% during the third quarter. RS Crum Inc. now owns 407 shares of the company’s stock valued at $360,000 after buying an additional 93 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Wolfe Research assumed coverage on Eli Lilly and Company in a research report on Friday, November 15th. They set an “outperform” rating and a $1,000.00 price target on the stock. Barclays decreased their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research report on Thursday, October 31st. Berenberg Bank upped their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. JPMorgan Chase & Co. upped their price target on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Finally, Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,007.94.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Up 4.5 %

Shares of LLY opened at $789.25 on Wednesday. The firm has a market cap of $749.25 billion, a P/E ratio of 85.32, a P/E/G ratio of 2.86 and a beta of 0.43. The stock has a 50 day simple moving average of $859.30 and a two-hundred day simple moving average of $870.41. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. Eli Lilly and Company has a 1 year low of $561.65 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). The firm had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm’s quarterly revenue was up 20.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.10 EPS. On average, analysts forecast that Eli Lilly and Company will post 13.2 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.66%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.